New hope for newborn seizures: levetiracetam tested as First-Line treatment
NCT ID NCT02229123
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug levetiracetam as the first treatment for seizures in 18 full-term newborns who had brain injury from lack of oxygen at birth. The goal was to find the right dose and check if it is safe and effective at reducing seizure activity on brain recordings. The results could lead to a better option for controlling seizures in these fragile babies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Levetiracetam (an anti-seizure drug)
- What this could lead to
- If successful, this could provide a safer, more effective first-line treatment for seizures in newborns with brain injury.
- What could go wrong
- This is a small, early-phase study with only 18 babies, so results may not apply to all newborns. The drug may cause side effects like severe breathing problems or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Néonatologie
Rennes, 35000, France
-
Service de Néonatologie
Tours, 37 000, France
-
Service de Pédiatrie néonatale et réanimation
Rouen, 76031, France
-
Service de réanimation et service néonatale
Orléans, 45100, France
-
Service de réanimation néonatale
Angers, 49000, France
-
Service de réanimation néonatale
Lille, 59037, France
-
Service de réanimation néonatale
Reims, 51092, France
-
Service de réanimation néonatale et pédiatrique
Paris, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.